Validation of apixaban anti-factor Xa assay and impact of body weight
Direct oral anticoagulants (DOACs) are widely used as therapies for venous thromboembolism and other cardiovascular diseases. However, routine coagulation monitoring is not required, but may be clinically indicated in high risk populations including obese patients.
Source: Thrombosis Research - Category: Hematology Authors: Suman M. Wasan, Natalie Feland, Russell Grant, Christopher E. Aston Tags: Full Length Article Source Type: research
More News: Cardiology | Cardiovascular | Eating Disorders & Weight Management | Grants | Heart | Hematology | Obesity | Thrombosis